A new Beginning..., page-2381

I think you mean PPA between 73-78% and NPA between 71-86% and not just a throw-away 70% as you suggested. And I agree, worst case is they need to redo the trials during our next summer (which will likely mean their performance option share will be expired) and this time have a panel of adjudicators (at least 5) instead of just 2 and a 3rd for deadlock and make sure these adjudicator also use blood sample as part of their diagnosis and not just rely mostly on X-ray.

"ResApp announced in October that ResAppDx achieved a positive percent agreement between 73% and 78% and a negative percent agreement between 71% and 86% when compared to a clinical diagnosis for lower respiratory tract disease, asthma/reactive airway disease and primary upper respiratory tract disease. Results for pneumonia and bronchiolitis were less than 70% prompting the company to pursue further investigation of these indications in the US."